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ARTICLE
HATRIC-based identiﬁcation of receptors for
orphan ligands
Nadine Sobotzki1,6, Michael A. Schafroth 2, Alina Rudnicka3,7, Anika Koetemann1, Florian Marty 4,8,
Sandra Goetze1, Yohei Yamauchi 5, Erick M. Carreira2 & Bernd Wollscheid 1
Cellular responses depend on the interactions of extracellular ligands, such as nutrients,
growth factors, or drugs, with speciﬁc cell-surface receptors. The sensitivity of these inter-
actions to non-physiological conditions, however, makes them challenging to study using
in vitro assays. Here we present HATRIC-based ligand receptor capture (HATRIC-LRC), a
chemoproteomic technology that successfully identiﬁes target receptors for orphan ligands
on living cells ranging from small molecules to intact viruses. HATRIC-LRC combines a click
chemistry-based, protein-centric workﬂow with a water-soluble catalyst to capture ligand-
receptor interactions at physiological pH from as few as 1 million cells. We show HATRIC-
LRC utility for general antibody target validation within the native nanoscale organization of
the surfaceome, as well as receptor identiﬁcation for a small molecule ligand. HATRIC-LRC
further enables the identiﬁcation of complex extracellular interactomes, such as the host
receptor panel for inﬂuenza A virus (IAV), the causative agent of the common ﬂu.
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Physiological ligand-receptor interactions are typically of lowafﬁnity and occur under native conditions, making themdifﬁcult to study in vitro1. Thus, the receptors for many
ligands have not been identiﬁed. Ligand-based receptor capture
(LRC) technology partly overcame these difﬁculties and enabled
the identiﬁcation of ligands for orphan N-glycoprotein-receptors
using the tri-functional reagent TRICEPS2,3 and modiﬁcations
thereof using a cross-linker containing an aldehyde-reactive
aminooxy group, a sulfhydryl, and a biotin group (ASB)4.
Application of TRICEPS-LRC and ASB in different biological
systems revealed the need to redesign the ﬁrst-generation tech-
nologies: TRICEPS-LRC was intentionally designed to enable the
identiﬁcation of ligand-bound receptors solely based on formerly
N-glycosylated peptides. O-glycosylated receptors and N-
glycosylated receptors, whose deamidated peptides were not
detectable by mass spectrometry, were eventually missed by this
strategy. However, this peptide-based strategy beneﬁtted from the
ability to ﬁlter for deamidated receptor peptides as indicators of
direct TRICEPS-crosslinking and ligand-binding. In contrast, in
ASB, tryptic digestion is performed directly on Streptavidin
beads, which enables protein-level afﬁnity puriﬁcation, enabling,
in principle, the identiﬁcation of receptors through non-
glycopeptides. However, direct digestion of proteins bound to
Streptavidin beads leads to major contaminations with strepta-
vidin peptides, impairing identiﬁcation and label-free quantiﬁ-
cation of receptor peptides. Furthermore, ASB requires
performing a two-step reaction in order to couple the ligand to
the cross-linker, and biotin transfer from ligand to receptor is
mediated by reduction of a disulﬁde bond, making its application
sensitive to reductive environments. Additionally, similar to ﬁrst-
generation TRICEPS-LRC, ASB requires high amounts of starting
material (50 million cells or 5–7 150 mm plates) and captures
ligand–receptor interactions in presence of a catalyst for oxime
formation at non-physiological pH 8, compared to pH 6.5 for
TRICEPS-LRC. The pH of the microenvironment directly inﬂu-
ences the afﬁnity between a ligand and its receptor, exempliﬁed
by ligands that are internalized upon receptor binding: The afﬁ-
nity for the receptor is high at pH 7.4 on the surface of living cells,
but decreases upon acidiﬁcation (pH 6.5) in the endosome,
leading to release of the ligand from the receptor. A prime
example of this is folate, which has an afﬁnity for folate receptor
alpha (FOLR1) that is 2000 times lower at pH 6.5 than at pH 7.45.
Consequently, the folate receptor has not been detected by
TRICEPS-LRC in the past, highlighting the need for a next-
generation LRC suited for receptor deorphanization at physio-
logical pH. Here we develop a new LRC technology with catalyst-
enhanced cell surface labeling and protein-level afﬁnity puriﬁca-
tion that enables the capture of ligand-receptor interactions at pH
7.4 from as few as 1 million cells.
Results
Development of a HATRIC-based LRC workﬂow. The next-
generation LRC technology is based on a new tri-functional
compound, HATRIC, with an acetone-protected hydrazone, an
N-hydroxysuccinimid (NHS), and an azide (Fig. 1a, Supple-
mentary Note 1). First, the ligand is linked through a primary
amine to the NHS-moiety of HATRIC (Fig. 1b). Second, living
cells are mildly oxidized with sodium-meta-periodate to generate
aldehydes from cell surface carbohydrates. During the whole
experiment, cells are kept on ice to prevent any receptor-
mediated internalization events. Third, the HATRIC-ligand
conjugate is added to the cells in the presence of catalyst 5-
methoxyanthranilic acid (5-MA) and receptor-capture is per-
formed at pH 7.4. The ligand enhances local HATRIC reactivity
in the vicinity of the target receptor or receptors, and receptor
aldehydes react with the acetone-derived hydrazone of HATRIC.
In the control, the HATRIC-conjugated ligand is applied to the
cells in the presence of an excess unmodiﬁed ligand. Here,
the out-competed ligand–HATRIC conjugate reacts randomly
with cell surface glycoproteins. As alternative controls, HATRIC
can be quenched with glycine (negative control) or a ligand with
known target receptors can be employed as a positive control (not
depicted in Figure 1). After the reaction, cells are lysed, and azide-
tagged surface proteins are afﬁnity-puriﬁed by linking azide-
tagged proteins to alkyne agarose using copper-based click
chemistry6. Trypsin-mediated proteolysis of bead-bound proteins
releases the unglycosylated peptides. These peptides are analyzed
with high-accuracy mass spectrometry using data-dependent
acquisition and ﬁltered for known and predicted cell surface
proteins. The quantitative comparison to the competitive control
reaction reveals speciﬁc enrichment of target cell surface recep-
tors for the ligand. The novel workﬂow renders HATRIC-LRC
independent of the PNGase F deglycosylation reaction, ultimately
enabling a more robust relative quantiﬁcation of cell surface
receptors than is possible with ﬁrst-generation LRC.
To enable HATRIC-LRC under physiological conditions, it was
necessary to accelerate the reaction of hydrazines with aldehydes,
which is slow at neutral pH7. Aniline has been exploited to
catalyze similar reactions efﬁciently8; however, the cytotoxicity at
the required concentration limits use with living cells9. Aniline-
derived water-soluble catalysts have been described that sub-
stantially improve catalysis of hydrazone formation, but none had
been tested in biological systems10. Evaluation of a number of
aniline derivatives regarding their solubility, cytotoxicity and
capability to enhance hydrazone formation between aldehydes on
cell surface proteins and the HATRIC-hydrazide on living cells
led to the identiﬁcation of 5-methoxyanthranilic acid (5-MA,
Fig. 1c, Supplementary Fig. 1). 5-MA catalyzed hydrazone
formation at a non-toxic concentration at pH 7.4 more efﬁciently
than 2-amino-4,5-dimethoxy benzoic acid (ADA) (Fig. 1c).
Additionally, replacing the original Triﬂuoroacetyl-protection
group of TRICEPS by an acetone-derived protection group in
HATRIC enabled higher yield of hydrazone formation on living
cells. Last, we conﬁrmed that, under the chosen conditions,
HATRIC does not penetrate cells avoiding contamination with
intracellular proteins (Supplementary Fig. 2).
Validation of HATRIC-based LRC. We validated HATRIC-LRC
demonstrating capture of epidermal growth factor receptor
(EGFR) using epidermal growth factor (EGF) as a ligand in an
experiment with living H-358 cells (Fig. 2a). When initially
quantifying all identiﬁed proteins across samples, we found 9
proteins signiﬁcantly enriched in the EGF-captured samples, but
only three of them were cell surface proteins, and EGF as ligand
dropped below signiﬁcance level. Statistical scoring of protein
candidates is based on the number of peptides identiﬁed per
proteins, which leads to bias towards larger proteins or proteins
whose peptides are easily detectable in MS (e.g., 19 features were
quantiﬁed and scored statistically for EGFR, whereas only 1
peptide was quantiﬁed and scored for EGF). In order to overcome
this bias, we used a ﬁlter for known and predicted cell surface
proteins prior to statistical scoring to rescue receptor candidates
where most peptides are hardly detectable via MS (e.g., due to
decreased solubility) (Supplementary Fig. 3; Supplementary
Data 1–3). Applying this ﬁlter prior to statistical analysis, we
correctly found EGF signiﬁcantly enriched and identiﬁed ﬁve
other EGF receptor candidates that have not been described
before (Supplementary Table 1, Supplementary Data 4 and 5),
namely monocarboxylate transporter 4 (SLC16A3), ﬁlamin-A
(FLNA), peroxisomal 3-ketoacyl-CoA thiolase (ACAA1),
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Gly-HATRIC-DIBO-AF488, 1.5mM NaIO4, pH 7.4
Gly-HATRIC-DIBO-AF488, 1.5mM NaIO4, pH 6.5
Gly-HATRIC-DIBO-AF488, 1.5mM NaIO4, 5mM ADA, pH 7.4
Gly-HATRIC-DIBO-AF488, 1.5mM NaIO4, 5mM 5MA, pH 7.4
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Fig. 1 HATRIC-LRC enables ligand-based receptor capture. a Structure of hydrazone (highlighted in magenta) and azide (highlighted in turquoise)
containing tri-functional compound HATRIC (NHS ester highlighted in blue). Mw= 1171.4 gmol−1 (synthesis described in Supplementary Note 1). b
Workﬂow of HATRIC-LRC for identiﬁcation of target receptors of ligands on living cells. First, living cells are mildly oxidized with 1.5 mM NaIO4. HATRIC,
conjugated to the ligand of interest, is added to living cells. The ligand selectively directs HATRIC to its glycoprotein target receptor, where HATRIC reacts
to generate azide-tagged cell-surface glycoproteins catalyzed by 5-MA. In order to identify target receptors of orphan ligands, a dual track experimental
setup is employed. In the control, the HATRIC-conjugated ligand is applied to the cells in the presence of an excess unmodiﬁed ligand. Alternatively,
HATRIC can be quenched with glycine for a negative control or a ligand with known target receptors can be employed as a positive control (not depicted in
ﬁgure). After lysis and afﬁnity puriﬁcation of azide-tagged proteins with unbound proteins removed by harsh washing, peptides are proteolyzed with
trypsin. Peptides are identiﬁed with high-accuracy mass spectrometry in a data-dependent acquisition mode followed by quantitative comparison of
peptide fractions? from experiment and control to reveal speciﬁc enrichment of candidate cell surface receptors. Target receptors are deﬁned as proteins
that have a fold change of >1.5 compared to the control as well as an FDR-adjusted p value (Benjamini–Hochberg method) equal to or smaller than 0.05,
corresponding to a target receptor window in the volcano plot that is framed by dotted lines and highlighted in red. c Flow cytometry traces of U-2932 cells
incubated with HATRIC conjugated to dibenzocyclooctyne-Alexa Fluor 488 (DIBO-AF488) at pH 6.5 or pH 7.4 in the presence or absence of
organocatalyst 5-methoxyanthranilic acid (5-MA) (structure shown, Mw= 167.16 g mol−1) or 2-amino-4,5-dimethoxy benzoic acid (ADA). HATRIC was
quenched with glycine (Gly−) to avoid potential reaction of HATRIC’s NHS-ester with amino groups at the cell surface. Shift to the right indicates more
efﬁcient labeling with HATRIC-DIBO-AF488
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transmembrane emp24 domain-containing protein 7 (TMED7)
and sarcoplasmic/endoplasmic reticulum calcium ATPase 1
(AT2A1) (Supplementary Table 1). Reports of direct interactions
between these proteins and EGF are not available, but it was
shown before that SLC16A3 co-locates with CD147 in breast
cancer cells11, which in turn is associated with EGFR in similar
lipid domains12, suggesting that SLC16A3 resides in the neigh-
borhood of EGFR at the cell surface13.
Identifying cell surface receptors from 1 million cells. As
HATRIC-LRC is based on protein-level puriﬁcation, more than
one peptide is commonly identiﬁed per protein, such as exem-
pliﬁed by EGFR (Supplementary Fig. 4). Therefore, we investi-
gated the HATRIC-LRC detection limit with respect to the
amount of starting material needed for successful receptor iden-
tiﬁcation. From as little as one million MDA-MB-231 cells per
replicate, we were able to unambiguously identify EGFR as the
receptor for HATRIC-coupled anti-EGFR antibody and trans-
ferrin receptor protein 1 (TFR1) as the receptor for HATRIC-
coupled Holo-transferrin (TRFE) (Fig. 2b, Supplementary Data 6
and 7), which was not possible with TRICEPS-LRC (Supple-
mentary Figures 5 and 6, Supplementary Data 8
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Fig. 2 HATRIC-LRC identiﬁes target receptors for ligands ranging from small molecules to intact viruses. All results of HATRIC-LRC experiments are
presented in volcano plots, where fold changes of proteins are shown with their respective log-transformed, fold changes are also log transformed false-
discovery rate (FDR)-adjusted p values. Target receptors are deﬁned as proteins that have a fold change of greater than 1.5 compared to the control as well
as a p value equal to or smaller than 0.05 (Benjamini–Hochberg method), corresponding to a target receptor window in the volcano plot that is framed by
dotted lines. All experiments were performed in triplicates per condition, except for the H3N2, where quadruplicates were produced. a HATRIC-LRC with
EGF on 20 million H-358 cells. In the negative control, HATRIC was quenched with glycine to map the off-target reaction of HATRIC on the same cell line.
The ligand and the known target receptor are highlighted in magenta. b HATRIC-LRC experiments with EGF and TFRE were performed on 1 million MDA-
MB-231 cells. In this experiment, two ligands with known receptors served as controls for each other to benchmark the ability to perform HATRIC-LRC with
as little as 1 million cells. The ligands and known target receptors are highlighted in magenta. c Folate-based HATRIC-LRC was performed on 20 million
folate-starved HeLa Kyoto cells per replicate. In the control, six-fold excess of free folate was used to compete with binding of folate-HATRIC. The target
receptor FOLR1 is highlighted in magenta. d IAV-based HATRIC-LRC was performed on 20 million A549 lung adenocarcinoma cells per replicate. In the
positive control, insulin was used as ligand, and insulin receptors were correctly identiﬁed. In the IAV-target receptor window, magenta-colored red dots
highlight receptors that showed an inhibitory effect on IAV cell entry whereas turquoise dots blue highlight receptors that facilitated IAV cell entry in a
siRNA-based knockdown experiment (Fig. 2e). e Effect of siRNA-mediated depletion of candidate receptors on IAV infection of A549 cells. Experiments
were conducted in triplicates. Infection scores from siRNA-treated samples were normalized to control samples transfected with non-targeting siRNA
(shown in gray). The data are presented as boxplots with whiskers from minimum to maximum values. Boxes extend from the 25th to 75th percentiles. The
line in the middle of the boxes depicts the median. The dotted line on the plot shows the median of control group? (normalized to 1). Magenta and
turquoise Red and green boxes highlight receptors that showed an inhibitory or facilitative effect on IAV cell entry (Magenta Red: infection score decreased
by >50%, turquoise green: infection score increased by >50% upon gene depletion)
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and 9). Where possible, we recommend the usage of 5–20 million
cells in order to detect low copy number receptors based on a
given sensitivity of the MS-instrument used for analysis.
Identiﬁcation of receptors for small molecule ligands. Next, we
investigated if HATRIC-LRC technology could be utilized to
identify receptors for small-molecule ligands. Previous studies
have focused on high-afﬁnity interactions of small molecules with
cytoplasmic proteins, resulting in underrepresentation of cell-
surface proteins in these studies14. Cell surface interactions of
small molecules, however, are clearly important, especially for
their uptake into cells15. As a proof-of-concept, we investigated
interactions of folate, which is known to interact with the cell-
surface protein folate receptor alpha (FOLR1). We synthesized a
folate-HATRIC conjugate (Supplementary Note 2) guided by
available structural data on the folate-FOLR1 complex16–18. We
incubated the folate-HATRIC conjugate with 20 million HeLa
Kyoto cells at pH 7.4. In the control, we competed with a six-fold
excess of unmodiﬁed folate. We detected interactions with FOLR1
and with a small set of further receptor candidates (Fig. 2c,
Table 1; Supplementary Data 10 and 11). None of these receptors
were previously described to directly interact with folate and we
did not identify any other known folate receptors. We speculate
that other folate receptors (e.g., FOLR2) were not identiﬁed as
their afﬁnity towards folate is lower than the afﬁnity of FOLR1,
i.e., FOLR2 has a two-fold reduced afﬁnity for folate compared to
FOLR1, or because they are not expressed in HeLa Kyoto cells19.
Related approaches studied methotrexate-based labeling of
FOLR1, but did not investigate whether the compound also binds
to other proteins18. This experiment shows that HATRIC-LRC
can be used as a screening method to identify relevant receptor
candidates for small-molecules that can be functionally validated
in subsequent experiments.
Identiﬁcation of receptor candidates for inﬂuenza virus. We
next explored whether HATRIC-LRC could be used to identify
entry facilitators for viruses. Currently, the contribution of cell-
surface proteins as entry facilitators remains poorly understood.
Viruses such as Inﬂuenza A virus (IAV) are known to have
multiple pathways of entry that depend on host cell type, avail-
ability of cell-surface receptors, and state of cell polarization20. To
infect cells, IAV-particles ﬁrst attach to cell surface sialyl-oligo-
saccharides, which are recognized by the IAV surface glycopro-
tein hemagglutinin (HA)21. This interaction results in virus
attachment to the host cell but can not trigger cell entry, as sialic
acids do not possess signaling capacity22. After endocytosis, the
virus travels through the endocytic pathway. In late endosomes,
the low pH initiates viral fusion, followed by completion of
uncoating, penetration, and infection. Genome-wide RNAi stu-
dies have revealed a number of protein-based receptor candidates
for IAV, but their precise roles in infection remain unclear23. We
used HATRIC-LRC to shed light on the complex interactions
between IAV and its host cells. Human IAV H3N2 (strain X-31)
was coupled to HATRIC and it was demonstrated that, although
coupling reduced IAV endocytosis, the particles used similar
endocytic pathways to the wild-type virus (Supplementary Fig-
ures 7 and 8). We conducted H3N2-based HATRIC-LRC on 20
million human lung adenocarcinoma (A549) cells and compared
to the control ligand insulin. We identiﬁed 24 virus-interacting
candidates (Fig. 2d, Supplementary Table 2, Supplementary
Data 12 and 13).
Verifying inﬂuenza entry facilitator receptor candidates. To
determine whether candidate receptors impact IAV entry, we
depleted A549 cells of 21 of these proteins using short interfering
RNA (siRNA) and analyzed infection efﬁciency. siRNA-mediated
depletion of >70% was conﬁrmed by real-time RT-real time vs RT
PCR in 20 genes. We excluded cartilage-associated protein
(CRTAP) from further analysis as siRNA treatment failed to
deplete it (Supplementary Fig. 9, Supplementary Data 14).
Depletion of four proteins, phospholipase D3 (PLD3), ribophorin
I (RPN1), folate transporter 1 (SLC19A1) and vesicular integral-
membrane protein VIP36 (LMAN2) reduced IAV infection by
more than 50% relative to cells treated with control siRNA
(Fig. 2e, Supplementary Data 15). Depletion of RPN1 reduced
IAV infection by over 94%. RPN1 is a subunit of the proteasome
regulatory particle, and thus might have effects on cells that are
not directly related to viral entry. However, its presence at the cell
membrane indicates that RPN1 may serve as an IAV entry
facilitator that could be a target for pharmaceutical intervention.
In contrast, depletion of two other identiﬁed proteins, adipocyte
plasma membrane-associated protein (APMAP) and cleft lip and
palate transmembrane protein 1 (CLPTM1), led to an increase of
infection by over 70% (Fig. 2e), indicating that these factors
restrict viral entry under physiological conditions. Of the receptor
candidates identiﬁed using HATRIC-LCR, none have been
implicated previously in mediating H3N2 infection. However, it
has been shown that related phospholipase γ1 (PLC-γ1) signaling
is activated by IAV H1N1 and mediates efﬁcient viral entry in
Table. 1 Folate-receptor candidates identiﬁed using folate-based HATRIC-LRC
Protein name Gene name Uniprot accession log2-transformed fold change FDR-adjusted p value
Vitronectin VTN P04004 2.22 0.00
CD166 antigen ALCAM Q13740 2.08 0.00
CD44 antigen CD44 P16070 2.03 0.00
Mucin-16 MUC16 Q8WXI7 1.97 0.00
Folate receptor alpha FOLR1 P15328 1.90 0.00
CD97 antigen CD97 P48960 1.90 0.00
Vasorin VASN Q6EMK4 1.69 0.00
Podocalyxin PODXL O00592 1.61 0.00
Complement decay-accelerating factor CD55 P08174 1.29 0.00
Endoglin (CD105) ENG P17813 1.29 0.00
Neural cell adhesion molecule L1 L1CAM P32004 1.27 0.00
Alpha-2-HS-glycoprotein AHSG P02765 0.97 0.00
Cell surface glycoprotein MUC18 MCAM P43121 0.96 0.00
Integrin alpha-6 (CD49F) ITGA6 P23229 0.91 0.03
Integrin alpha-5 (CD49E) ITGA5 P08648 0.87 0.04
Integrin alpha-V ITGAV P06756 0.83 0.03
Carboxypeptidase M CPM P14384 0.68 0.03
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human epithelial cells24. Of the 5 independent genome-wide
siRNA screens on IAV that were published, three have been
validated25–27. Of the 129, 168 and 219 genes, respectively, that
were validated as hits from these three screens, 34 were shared in
two or more. Only 3 genes (ARCN1, ATP6AP1, and COPG) were
shared among all three. A comparison of our top seven decreaser
genes (RPN1, PLD3, SLC19A1, LMAN2, ASPH, CD151, RPN2)
with the 34 genes revealed mild functional overlap28. We also had
4 strong hits (i.e., increased or decreased infection by more than
70%) out of 20 validated genes—a hit rate of 20%—which is
considerably higher compared to the genome-wide screens
(~1%). The identiﬁcation of these potential IAV entry facilitators
suggests potential for new lines of inﬂuenza research and therapy.
Discussion
Given the experimental setup, the candidates identiﬁed from
HATRIC-LRC experiments can generally result from the follow-
ing four scenarios: (1) there is a direct interaction of the ligand
with the target receptor; (2) the protein is in close proximity of
the target receptor (“neighborhood protein”); (3) the protein
is upregulated in response to treatment with the ligand and is
overrepresented in the background binding of HATRIC (e.g., we
use approximately 8 times more EGF than is used for stimulation
experiments) or (4) the identiﬁed candidate is a false positive.
A single HATRIC-LRC experiment does not allow us to
delineate which type of interaction is taking place, but the vali-
dation experiments and the cited data clearly underline the
relevance of the identiﬁed proteins. The analysis pipeline was
optimized to allow identiﬁcation and ranking of receptor candi-
dates. However, the resulting data have to be analyzed carefully,
and more stringent receptor spaces can be deﬁned based on the
identiﬁcation of positive control receptors or the ligand (e.g.,
EGF). Identiﬁed candidates need validation in tailor-made follow-
up experiments, such as siRNA-based approaches.
We demonstrated that HATRIC-LRC enables ligand-receptor
identiﬁcation from as few as 1 million cells at physiological pH
through new chemistry combining HATRIC, a water-soluble
catalyst, and click chemistry-based protein-level afﬁnity pur-
iﬁcation in a competition-based workﬂow. Even though
HATRIC-LRC is a screening technology that leads to candidate
receptors, including potentially false positive receptor candidates,
which need to further validated, its ability to detect biologically
meaningful ligand-receptor interactions remains unmatched. The
power of HATRIC-LRC to detect functionally relevant cell sur-
face interactions was demonstrated using ligands ranging from
small molecules to intact inﬂuenza A virus particles. The IAV
application showed that HATRIC-LRC is able to identify binding
partners of multivalent virus particles on the cell surface that are
potentially organized in a viral synapse. In future applications,
HATRIC chemistry should enable the analysis of post-
translational modiﬁcations of signaling competent receptors
and, given the drastically increased sensitivity of the HATRIC
technology, applications using rare biological or clinical speci-
mens, opening up new avenues for biomedical research.
Methods
Chemicals. All chemicals and cell culture reagents were from Sigma-Aldrich unless
stated otherwise.
Synthesis of HATRIC. The trifunctional reagent HATRIC, containing an acetone-
protected hydrazone and an azide afﬁnity tag, was synthesized from Fmoc-Lys
(Boc)-OH in seven steps using standard peptide coupling conditions.
Synthesis of folate-HATRIC. We synthesized a Boc-protected amine-functiona-
lized folate derivative by peptide coupling of a glutamic acid derivative with pteroic
acid. After deprotection, the resulting amine was conjugated to HATRIC, resulting
in a folate-HATRIC conjugate (Supplementary Note 2). Structural data of the
folate-FOLR1 complex as well as previous modiﬁcation of folate at this site sup-
ported the choice for the conjugation site16–18.
Mammalian cell culture. Cells were grown at 37 °C and 5% ambient CO2. HeLa
Kyoto (ATCC), MDA-MB-231 (ATCC), and A549 cells (ATCC) were grown to
~80% conﬂuence in 140 × 20mm dishes (NunclonTM Delta Airvent, Thermo
Fisher) with Dulbecco’s Modiﬁed Eagle’s Medium, high glucose, GlutaMAXTM
supplement (DMEM, Thermo Scientiﬁc), 10% fetal bovine serum (FBS), and 1%
penicillin-streptomycin. H-358 (ATCC CRL-5807) and U-2932 (ATCC) cell lines
were cultured in RPMI 1640 with GlutaMAXTM, 1% penicillin-streptomycin, and
10% FBS. Prior to HATRIC-LRC experiments with folate, HeLa cells were starved
for 48 h in folate-free RPMI (Gibco).
Catalyst cytotoxicity assays. MDA-MB 231 cells (20.000 cells per well in a 96-
well plate) were treated with the indicated concentrations of catalyst in DMEM (pH
adjusted to 7.4, 1% Pen/Strep) for 1.5 h at 37 °C. Supernatant was replaced by 100ul
DMEM with 10% alamarBlue™ reagent (ThermoScientiﬁc) and incubated for 5 h at
37 °C in the dark. Assay was read out by a ﬂuoreader (Ex: 545 nm, Em: 590 nm,
automatic gain).
Confocal microscopy imaging. HATRIC was pre-coupled to equimolar amine-Cy3
(Lumiprobe) in 25 mM HEPES (pH 8.2) for 1.5 h at RT and 300 rpm in the dark.
MDA-MB-231 cells cultured on coverslips were oxidized with 1 ml of 1.5 mM
sodium periodate in PBS, pH 6.5 for 15min and labeled with 6 µM HATRIC-Cy3 or
amine-Cy3 (Control w/o HATRIC) in 1 ml PBS with 5 mM 5-MA (pH 7.4) for 1.5 h
at 4 °C shaking in the dark. As a cell surface marker, cells were labeled with 0.5ml 1
mM sulfo-NHS-Cy5 (Lumiprobe). Nuclei were stained with 0.5 ml 1 µg ml−1
Hoechst (Molecular Probes H1399) for 10min at 4 °C. Cells were ﬁxed with 4%
paraformaldehyde for 10min at RT, mounted with anti-fade mounting medium
(Molecular Probes Prolong Gold Antifade reagent P36934) and analyzed by con-
focal microscopy (Leica TCS SP2). For a permeabilized control, cells were ﬁrst
stained with sulfo-NHS-Cy5 and ﬁxed, and then permeabilized with 0.1% Triton
X-100 for 10min at RT, before oxidation and labeling with HATRIC-Cy3.
Visualization of cell surface azidylation with HATRIC. Amine-reactive groups of
HATRIC were quenched with 10-fold excess glycine, and the HATRIC azide was
reacted with 50 mM Click-IT Alexa Fluor 488 DIBO Alkyne (DIBO-AF488,
Thermo Fisher Scientiﬁc) in a copper-free click chemistry reaction in 25 mM
HEPES, pH 8.2 for 60 min. Per replicate, 1 × 106 U-2932 cells were oxidized with
1.5 mM NaIO4 for 15 min at 4 °C in PBS (pH 6.5) with slow rotation in the dark or
left untreated. Cells were washed twice with phosphate-buffered saline (PBS, pH
7.4) to remove residual NaIO4. Cells were labeled with 75 μM glycine-quenched
HATRIC-DIBO-AF488 conjugates for 60 min at 4 °C with slow rotation in the
presence or absence of 5 mM 5-MA or 5 mM ADA. The pH was adjusted to 6.5
with H3PO4 or to 7.4 with NaOH prior to addition to cells. Unstained cells were
washed twice with FACS buffer (PBS containing 1% FBS). Stained cells were
washed four times with FACS buffer and resuspended in 500 μl FACS buffer. Cells
were analyzed on an Accuri C6 Flow Cytometer (BD Biosciences). The data were
analyzed with FlowJo v.10.
HATRIC-based ligand-receptor capture. All experiments were performed in
triplicates per condition, except for the H3N2, which was produced in quad-
ruplicates. Each experiment was reproduced at least once in the laboratory.
HATRIC-LRC was performed in seven steps, as follows: (1) Coupling of trifunc-
tional compound: Ligand (100 μg insulin, 100 μg EGF, 100 μg anti-EGFR antibody
(E2156-200UL, Sigma-Aldrich), 100 μg transferrin or or 5 × 108 plaque-forming
units of X-31) was reacted with 70 μg HATRIC (100 mM stock solution in DMSO)
for 1.5 h with slow rotation at 22 °C in 50 μl 25 mM HEPES (pH 8.2). For
HATRIC-small molecule conjugates, pre-coupling was not necessary. (2) Collec-
tion of cells and oxidation: Per replicate, the indicated number of cells were col-
lected by gentle scraping (adherent cell lines) or centrifugation (suspension cell
lines) and collected at 4 °C. Cells were resuspended in PBS (pH 6.5) and oxidized
for 15 min with 1.5 mM NaIO4 at slow rotation at 4 °C in the dark. Cells were
washed once with PBS (pH 6.5) and resuspended in 10 ml PBS containing 5 mM 5-
MA (pH 7.4). (3) Receptor capture with HATRIC: HATRIC-ligand solution (50 μl)
was added to a ﬁnal concentration of 6 μM HATRIC. For folate-HATRIC-LRC, a
six-fold excess free compound was added to control reactions. Cells were incubated
for 90 min at slow rotation and 4 °C. Cells were pelleted, washed twice with PBS
(pH 7.4) to remove unbound HATRIC, and lysed with 8M Urea, 0.1% RapiGest SF
(Waters) containing protease inhibitors (cOmplete, Roche), pH 8. (4) Cell lysis:
Cells were lysed using three 20 s sonication pulses in a VialTweeter. Debris was
pelleted by centrifugation at 16,000 × g for 10 min (4 °C), and supernatants placed
on ice. (5) Click chemistry-based enrichment: Per replicate, 200 μl alkyne agarose
(Jena Bioscience) was washed three times with 1.8 ml MilliQ (MQ) water. The
lysates were added to the beads, and 1 ml click chemistry buffer was added with
ﬁnal concentrations of 1 mM CuSO4, 6.25 mM THPTA, and 10 mM sodium
ascorbate. The copper-catalyzed azide-alkyne cycloaddition reaction was conducted
for 18 h with slow rotation at room temperature. (6) Stringent washing of resin:
Agarose beads were pelleted by centrifugation for 4 min at 300 × g, supernatant was
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removed, and beads were washed twice with 1.8 ml MQ water. Cells were resus-
pended in 1 ml sodium dodecyl sulfate (SDS) wash buffer (1% SDS, 100 mM Tris,
250 mM NaCl, 5 mM EDTA, pH 8), and bead-bound proteins were reduced with 5
mM Tris(2-carboxyethyl)phosphine (TCEP) for 15 min at 55 °C and 15 min at
room temperature. Beads were pelleted at 300 × g for 4 min to remove supernatant.
Bead-bound proteins were alkylated with 40 mM iodoacetamide for 30 min at
room temperature in the dark. Beads were transferred to MoBiCol classic 35-μm
ﬁlters (MoBiTec) and washed with 10 ml SDS wash buffer, 10 ml 8 M urea/100 mM
Tris, 5 ml 5M NaCl, 1.5 ml 80% isopropanol, 5 ml 100 mM NaHCO3 (pH 11), 5 ml
50 mM ammonium bicarbonate (60 °C), and 5 ml 20% acetonitrile. Then beads
were transferred to fresh MoBiCols. (7) On-bead tryptic digestion: Beads were
resuspended in 400 μl digestion buffer (100 mM Tris, 2 mM CaCl2, 10% acetoni-
trile) and 2 μl sequencing grade modiﬁed trypsin (Promega) was added and
incubated for 16 h at 37 °C. The tryptic peptide fraction was collected, and beads
washed twice with 50 mM ammonium bicarbonate to remove all released peptides
from beads. The resulting peptide fractions were acidiﬁed with 10% formic acid
(FA) to pH 3–4 prior to desalting in UltraMicroSpin C18 Columns (Nestgroup)
with 5–60 μg capacity for tryptic peptide fraction according to manufacturer’s
instructions. The eluted peptides were dried in a speedvac and stored at −80 °C.
LC-MS/MS analysis. Tryptic peptide fractions and lysates were reconstituted in
20 μL 3% acetonitrile/0.1% FA/doubly distilled water, and 1 ug per sample was
loaded onto an EASY-nano-HPLC system (Proxeon) equipped with a RP-HPLC
column (75 μm× 10.5 cm) packed in-house with 10 cm stationary phase (Magic
C18 AQ 1.9 μm, 200 Å, Michrom BioResources). The HPLC was coupled to a
QExactive plus MS (Thermo Scientiﬁc) equipped with a nano-electrospray ion
source (Thermo Scientiﬁc). Peptides were loaded onto the column with buffer A
(0.1% FA) and were eluted with 300 nL min−1 buffer B (99.9% ACN, 0.1% FA).
Subsequently, the column was washed with 98% buffer B. The tryptic peptide
fractions were eluted with a 100 min gradient of 5–20% B followed by a 20 min
gradient from 20–28% B, and a ﬁnal 4-min step from 28–50% B. The column was
washed with 98% buffer B. The MS was operated in data-dependent manner, with
an automatic switch between MS to MS/MS scans. High-resolution MS scans were
acquired (70,000, target value 106) within 300–1700 m/z. The 15 most intense
precursor ions were fragmented using higher-energy collisional dissociation (HCD)
to acquire MS/MS scans (minimum signal threshold 420, target value 5 × 104,
isolation width 1.5 m/z). Unassigned and singly charged ions were excluded from
HCD, and dynamic exclusion was set to 30 s.
Data analysis. RAW data were converted to mzML using MSconvert. Fragment
ion spectra were searched with COMET (v27.0) against UniprotKB (v57.15, Homo
sapiens) containing common contaminants. The precursor mass tolerance was set
to 20 p.p.m. Carbamidomethylation was set as a ﬁxed modiﬁcation for cysteine and
oxidation of methionine as a variable modiﬁcation. Probability scoring was done
with PeptideProphet and ProteinProphet of the Trans-Proteomic Pipeline (v4.6.2).
Protein identiﬁcations were ﬁltered for a FDR of ≤1%. For label-free quantiﬁcation,
proteins were ﬁltered for cell surface location, based on the cell surface protein
atlas29 and the human surfaceome (Omasits, U. et al., manuscript in preparation;
Supplementary Table 2). The respective ligand was added to the ﬁlter list if not
contained. For the HATRIC-LRC screen with 1 million cells as starting material, no
cell surface ﬁltering was applied. Non-conﬂicting peptide feature intensities
extracted with Progenesis QI (Nonlinear Dynamics). The output of Progenesis is a
list of quantiﬁed spectral features representing peptides of cell surface proteins with
multiple charge states and differential modiﬁcations. In MSstats3 (v3.2.2), the
features were log-transformed, and then subjected to constant normalization30.
Protein fold changes and their statistical signiﬁcance between paired conditions
were tested using at least two fully tryptic peptides per protein or one fully tryptic
peptide per protein for the 1 million cell experiment. The minimum intensity for
each peptide feature was set to 500. Tests for signiﬁcant changes in protein
abundance across conditions are based on a family of linear mixed-effects models.
In the last step of the analysis, p values are adjusted for multiple comparisons to
control the experiment-wide FDR at a desired level using the Benjamini–Hochberg
method. Proteins were considered candidates if they showed a fold-change of 1.5 or
higher and an adjusted p value of 0.05 or lower.
qPCR analysis of siRNA-mediated gene depletion. qPCR analysis of the efﬁ-
ciency of siRNA-mediated gene knockdown was performed using Power SYBR®
Green Cells-to-CT™ Kit (Ambion) and Rotor Gene real-time PCR cycler (Qiagen).
The ΔΔCq method was used to determine relative gene expression using HPRT as
the housekeeping gene.
IAV endocytosis assay. This assay was performed as described in ref.31. Brieﬂy,
cells were incubated with equal volume of virus (MOI= 50 for the control virus)
for 45 min on ice, and the bound virus was allowed to be internalized at 37 °C for
25 min. After washing, the cells were ﬁxed, washed with PBS, and the cell mem-
brane was stained with wheat germ agglutinin (WGA)-AF647 (Invitrogen) in PBS
(1:250) for 30 min at RT and washed again to remove unbound WGA-AF647. The
epitopes of extracellular HA were blocked overnight at 4 °C with Pinda (anti-HA
rabbit polyclonal, made in house) antibody (1:2000) in blocking buffer (PBS, 1%
BSA, 5% FCS), and the cells stained with secondary anti-rabbit IgG-AF594 con-
jugate (Invitrogen) (1:2500) in blocking buffer for 1 h at room temperature. After
ﬁxation in 4% formaldehyde (FA) in PBS for 20 min and washing, a permeabili-
zation solution (PS, 0.1% saponin, 1% BSA, 5% FCS in PBS) was added for 30 min
followed by incubation with a mouse monoclonal antibody speciﬁc for HA1 (made
in house, 1:100) in PS for 2 h at room temperature. After washing, the cells were
incubated with secondary anti-mouse IgG-AF488 (Thermo Fisher,
A-11001,1:2500) in PS for 1 h, and the nuclei were stained by Hoechst 33258
(Sigma) (1:10,000). Inhibitors against endocytosis mechanisms was used as follows:
the cells were pre-incubated with Dyngo-4a (Abcam) (50 µM), which blocks
dynamin and/or EIPA (80 µM), an amiloride that blocks Na+/H+ exchangers, for
30 min prior to infection. HATRIC-coupled or non-coupled virus was submitted to
endocytosis assay as described above using equal volumes of both virus samples.
The inhibitors were present throughout the duration of the experiment until
ﬁxation. Z-stacks were acquired using a Leica SP8 confocal microscope and the
internalized virus particles and extracellular particles were quantiﬁed using ImageJ.
IAV infection assay. This assay was performed as described in ref.31. Brieﬂy, cells
plated on 96-well µClear cell culture microplates were infected with control or
HATRIC-coupled IAV at a low MOI (0.2–0.5) in infection medium (DMEM, 0.2%
BSA, 50 mM HEPES pH6.8). 7 h after infection, the cells were washed and ﬁxed in
4% FA in PBS for 20 min at room temperature. The cells were stained using HB65
(anti-nucleoporotein) monoclonal antibody (H16-L10-4R5, ATCC HB-65) from
hybridoma supernatant (1:15) in PS for 30 min at room temperature. After sec-
ondary antibody and Hoechst staining were performed as above, the plates were
imaged using a Yokogawa CV1000 with a 10× objective. The acquired images were
analyzed using Cell proﬁler and an automated pipeline.
IAV plaque assay. This assay was performed as described in ref.31. Speciﬁcally, for
IAV titration, HATRIC-coupled and non-coupled virus was infected in Infection
PBS (PBS, 0.02 mM Mg2+, 0.01 mM Ca2+, 0.3% BSA) in 10-fold serial dilutions
onto a monolayer of MDCK II cells in 6-well plates. After 1 h of inoculation, the
unbound viruses were washed and the medium was replaced with MEM, 0.3% BSA,
0.1% FBS, 20 mM HEPES, 1.2% Avicel, 0.5 µg ml−1 TPCK-trypsin). After 3 days of
infection, the viable cells were stained with 0.5 mgml−1 MTT in PBS for 30 min.
Plaques were counted and the plaque-forming unit (PFU) ml−1 was calculated.
siRNA-mediated depletion of candidates and IAV infection. A549 cells (2500
cells/well) were reverse transfected with pooled siRNAs (Dharmacon) (4 siRNAs
targeting each gene) at a ﬁnal concentration of 20 nM using Lipofectamine
RNAiMax (Invitrogen) in 96-well optical-bottom Matrix plates (Thermo Scien-
tiﬁc). Three days after transfection, the cells were infected with IAV strain X-31
(H3N2) at 1.3 × 104 infectious units per well (as determined by TCID50 assay) in
infection medium (DMEM, 50 mM HEPES, pH 6.8, 0.2% BSA) for 7 h. IAV X-31 is
an H3N2 reassorted strain derived from the A/Puerto Rico/8/34 (PR8) and A/
Hong Kong/1/68 strains and was purchased from Virapur in puriﬁed form.
Infected cells were ﬁxed in 4% formaldehyde in PBS for 20 min. For detection of
viral nucleoprotein (NP) expression, cells were permeabilized in 0.1% Triton X-100
for 5 min in blocking buffer (PBS, 1% BSA), stained with anti-NP mAb HB65
(ATCC) for 60 min and then goat anti-mouse Alexa Fluor 488 secondary antibody
for 30 min. Nuclei were stained with Hoechst 33258 (Molecular Probes). Auto-
mated image acquisition was performed with an ImageXpress high-throughput
screening system (Molecular Devices) using a ×10 objective. Cell numbers and raw
infection indices for each well were determined using CellProﬁler and KNIME
software. Infection scores from siRNA-treated samples were normalized to control
samples transfected with non-targeting siRNAs. Kruskal–Wallis test was applied to
detect signiﬁcant differences between the groups (p value < 2.2e–16). Statistical
signiﬁcance was tested with a Mann–Whitney U test (Supplementary Data 14)
using custom made R-software code.
Data availability. All mass spectrometric data that support the ﬁndings of this
study are deposited to the public database MassIVE as RAW ﬁles [ftp://massive.
ucsd.edu/MSV000081228]. The authors declare all other data supporting the
ﬁndings of this study are available within the paper and its supplementary infor-
mation ﬁles.
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